Partnership revenue volatility
Quarterly fluctuations due to inventory phasing and frozen periods may persist through FY26, obscuring underlying growth.
SANOFIINDIA / bear-case history
Track the concerns that keep returning.
Sanofi India · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Competitive pressure in institutional business
Aggressive discounting by competitors in certain accounts and institutional business is impacting partnership sales.
GLP-1 market invasion
Rapid growth of GLP-1 drugs could cannibalize insulin sales, though Soliqua (GLP-1/insulin combo) may mitigate.